Literature DB >> 31395305

Quality of life in long term ventilated adult patients with Duchenne muscular dystrophy.

Grazia Crescimanno1, Francesca Greco2, Rosaria D'Alia2, Luigi Messina2, Oreste Marrone3.   

Abstract

The aim of this study was to evaluate quality of life (QoL) and its possible determinants in patients affected by Duchenne muscular dystrophy (DMD) in late stages of their disease, when non-invasive ventilation (NIV) is already established. Forty-eight DMD patients who were treated by NIV were enrolled. QoL was assessed by the Individualized Neuromuscular Quality of Life (INQoL) questionnaire. By this questionnaire, different aspects of QoL were assessed on a scale from 0 (best) to 100 (worst). In addition, motor and respiratory function tests were performed. Dysautonomia symptoms, sleep quality, sleepiness, anxiety, and depression were evaluated by validated questionnaires. The global INQoL score was 42.8 ± 19, reflecting a moderately altered QoL. The physical health domain was heavily impaired while the psychosocial domain was only mildly affected. Independence had the highest scores (81.1 ± 21.2), proving to be the most affected item. On multivariate analysis, maximal inspiratory pressure and Pittsburgh Sleep Quality Index, but not daily duration of NIV therapy, predicted global INQoL score. Respiratory impairment and sleep quality were independent predictors of poor QoL in DMD patients under NIV. Sleep quality in DMD is often disregarded, while it should be carefully addressed to ensure a better QoL.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Duchenne muscular dystrophy; Individualized neuromuscular quality of life; Respiratory impairment; Subjective sleep quality

Mesh:

Year:  2019        PMID: 31395305     DOI: 10.1016/j.nmd.2019.06.599

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  6 in total

1.  Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.

Authors:  Silvia Bonanno; Riccardo Zanin; Luca Bello; Irene Tramacere; Virginia Bozzoni; Luca Caumo; Manfredi Ferraro; Sara Bortolani; Gianni Sorarù; Mauro Silvestrini; Veria Vacchiano; Mara Turri; Raffaella Tanel; Rocco Liguori; Michela Coccia; Renato Emilio Mantegazza; Tiziana Mongini; Elena Pegoraro; Lorenzo Maggi
Journal:  J Neurol       Date:  2022-01-03       Impact factor: 4.849

2.  Respiratory function and therapeutic expectations in DMD: families experience and perspective.

Authors:  Claudia Brogna; Simona Lucibello; Giorgia Coratti; Gianluca Vita; Valeria A Sansone; Sonia Messina; Emilio Albamonte; Francesca Salmin; Gloria Ferrantini; Elisa Pede; Chiara Consulo; Lavinia Fanelli; Nicola Forcina; Giulia Norcia; Marika Pane; Eugenio Mercuri
Journal:  Acta Myol       Date:  2020-09-01

3.  Role Attainment in Emerging Adulthood: Subjective Evaluation by Male Adolescents and Adults with Duchenne and Becker Muscular Dystrophy.

Authors:  Holly L Peay; Barbara T Do; Neil Khosla; Pangaja Paramsothy; Stephen W Erickson; Molly M Lamb; Nedra Whitehead; Deborah J Fox; Shree Pandya; Kathi Kinnett; Jodi Wolff; James F Howard
Journal:  J Neuromuscul Dis       Date:  2022

4.  Objective and subjective measures of sleep in men with Muscular Dystrophy.

Authors:  Christopher I Morse; Gladys Onambele-Pearson; Bryn Edwards; Sze Choong Wong; Matthew F Jacques
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

Review 5.  Daytime noninvasive ventilatory support for patients with ventilatory pump failure: a narrative review.

Authors:  Paolo Banfi; Paola Pierucci; Eleonora Volpato; Antonello Nicolini; Agata Lax; Dominique Robert; John Bach
Journal:  Multidiscip Respir Med       Date:  2019-11-30

6.  Impact of Confinement in Patients under Long-Term Noninvasive Ventilation during the First Wave of the SARS-CoV-2 Pandemic: A Remarkable Resilience.

Authors:  Chloé Cantero; Patrick Pasquina; Melissa Dominicé Dao; Christine Cedraschi; Dan Adler; Jérôme Plojoux; Jean-Paul Janssens
Journal:  Respiration       Date:  2021-06-15       Impact factor: 3.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.